Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adicet Bio, Inc. - Common Stock
(NQ:
ACET
)
6.500
-0.140 (-2.11%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adicet Bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 Months
↗
October 02, 2026
Adicet Bio (NASDAQ:ACET) reported positive clinical data for prula-cel, its investigational allogeneic gamma delta CAR-T cell therapy, in patients with systemic lupus erythematosus, or SLE, including...
Via
MarketBeat
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
September 28, 2026
Via
Chartmill
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
September 28, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday?
↗
September 25, 2026
Via
Chartmill
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
September 25, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference
September 02, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update
September 01, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 31, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
↗
August 31, 2026
One of J&J's investments stands head-and-shoulders above the rest.
Via
The Motley Fool
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
August 27, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
↗
August 11, 2026
Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus...
Via
MarketBeat
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 05, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
July 21, 2026
From
Adicet Bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 25, 2026
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH)...
Via
Benzinga
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
↗
June 04, 2026
Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen...
Via
MarketBeat
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
May 14, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
May 13, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
March 12, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
January 30, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
January 07, 2026
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces Reverse Stock Split
December 26, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 05, 2025
From
Adicet Bio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 04, 2025
Via
Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 28, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
October 16, 2025
From
Adicet Bio, Inc.
Via
Business Wire
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2
↗
October 07, 2025
Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising $80 million to fund Phase 2.
Via
Benzinga
Tuesday's session: gap up and gap down stocks
↗
October 07, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
